Month: February 2021

The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the safety and tolerability of a booster vaccineDiscussions with regulatory authorities are ongoing regarding an additional registration-enabling study using an mRNA vaccine with a variant sequence; this would provide a flexible solution for rapidly adapting the vaccine for use against the B.1.351 lineage or other new strains that may emerge as possible immune escape virus variants Based on in-vitro studies conducted to date and observations from real world evidence, the Companies have not observed changes to neutralizing antibody levels that would predict a significant reduction in protection provided by two doses of BNT162b2New York and Mainz, Germany,...

Die Verabreichung einer dritten Dosis des Pfizer-BioNTech COVID-19-Impfstoffs BNT162b2 wird als Teil der Phase-1/2/3-Studie untersucht; die Teilnehmer der Phase-1-Studie erhalten eine 30µg-Dosis BNT162b2 zur Beurteilung der Sicherheit und Wirksamkeit als AuffrischungsimpfungLaufender Austausch mit Zulassungsbehörden über eine zusätzliche zulassungsrelevante Studie zum Einsatz eines mRNA-Impfstoffs mit einer variablen Sequenz; dies würde eine flexible Lösung für die schnelle Anpassung des Impfstoffs im Einsatz gegen die B.1.351-Linie oder andere neue Stämme darstellen, die als mögliche Immun-Escape-Virusvarianten auftreten könnten Die Unternehmen haben bisher in den durchgeführten in-vitro-Studien und anhand von Daten aus der praktischen Anwendung keine Veränderungen der neutralisierenden Antikörperlevel beobachten können, die auf eine...

To Nasdaq OMX Copenhagen A/SPublic announcement no. 487February 25th, 2021ECONOMIC KEY FIGURES FOR GLUNZ & JENSEN HOLDING A/S Q3 2020/21The Q3, 2020/21 of the fiscal year was reviewed and approved at the Board of Directors meeting today. The Board of Directors announces the following consolidated financial statements year to date (YTD) for Q3 (the first 9 months) of 2020/21.The Q3 result of the fiscal year 2020/21 has met the expectations under very difficult market conditions.HighlightsThe revenue for YTD Q3 2020/21 was adversely impacted by COVID 19 and amounted to DKK 104,2 million (2019/20: DKK 150,6 million).The order intake and revenue have also been negatively impacted by the COVID-19 disruptions.The process of strengthening earnings by streamlining by consolidating production and supply chain at the subsidiary in Slovakia...

– Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 –– Ended 2020 with $213.2 million in cash, cash equivalents and investments –– Company to host conference call and webcast today at 8:00 AM ET –CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.“2020 proved to be a year of important pipeline execution and corporate development at Jounce despite the challenges presented by the COVID-19 pandemic. As we enter...

ROCKFORD, Mich., Feb. 25, 2021 (GLOBE NEWSWIRE) — Wolverine World Wide, Inc. (NYSE: WWW) today reported financial results for the fourth quarter and full year ended January 2, 2021.“The Company delivered better-than-expected results for the fourth quarter and is poised to drive an accelerated recovery over the next twelve to eighteen months,” said Blake W. Krueger, Wolverine Worldwide’s Chairman and Chief Executive Officer. “During a year of unprecedented challenges, we took action focused on the rapidly changing consumer landscape. Our owned eCommerce revenue grew 50% in 2020, and we have planned further investment in this area to enable growth of 40% in 2021, significantly outpacing broader industry expectations. Our balance sheet is healthy, and our brands are well positioned in winning product categories with strong momentum....

ATLANTA, Feb. 25, 2021 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray,” “we,” “us” or “our”) (NYSE: GTN) today announced financial results for the fourth quarter ended December 31, 2020. Despite the impact of the novel coronavirus and its disease (collectively, “COVID-19”) on economic activity, our strong political revenues, prudent cost management, strategic sales initiatives and training, and focused management at every level during the last three quarters of 2020, and especially the fourth quarter of 2020, resulted in record operating results for the fourth quarter and the full-year. Key financial results are as follows:Our revenue for the fourth quarter of 2020 was $792 million, an increase of $213 million, or 37%, from the fourth quarter of 2019. The primary components of revenue were combined local and national broadcast...

Fourth quarter 2020 revenues of $711.2 million, up 4.4% versus prior year period on an as-reported basis; up 2.3% on a constant currency basisFourth quarter 2020 GAAP diluted EPS from continuing operations of $1.62, compared to $2.28 in the prior year periodFourth quarter 2020 adjusted diluted EPS from continuing operations of $3.25, down 0.9% versus prior year periodFull year 2020 revenues of $2.537 billion, down 2.2% versus prior year period on an as-reported basis; down 2.4% on a constant currency basisFull year 2020 GAAP diluted EPS from continuing operations of $7.10, compared to $9.81 in the prior year periodFull year 2020 adjusted diluted EPS from continuing operations of $10.67, down 4.3% versus prior year period2021 guidance range for GAAP revenue growth of between 10.0% and 11.5%2021 guidance range for constant currency revenue...

Series  RIKV 21 0615 RIKV 21 0915Settlement Date  03/01/2021 03/01/2021Total Amount Allocated (MM)  12,880 4,000All Bids Awarded At (Price / Simple interest)  99.678 / 1.097 99.318 / 1.249Total Number of Bids Received  13 11Total Amount of All Bids Received (MM)  17,180 6,400Total Number of Successful Bids  8 8Number of Bids Allocated in Full  8 7Lowest Price / Highest Simple Interest Allocated  99.678 / 1.097 99.318 / 1.249Highest Price / Lowest Simple Interest Allocated  99.722 / 0.947 99.399 / 1.099Lowest Price / Highest Simple Interest Allocated in Full  99.678 / 1.097 99.334 / 1.219Weighted Average of Successful Bids (Price/Simple Interest)  99.683 / 1.080 99.342 / 1.204Best Bid (Price / Simple Interest)  99.722 / 0.947 99.399 / 1.099Worst Bid (Price / Simple Interest)  99.545 / 1.552 99.290 / 1.300Weighted...

SINGAPORE, Feb. 25, 2021 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has entered into a securities purchase agreement to raise gross proceeds of approximately $18 million resulting from the sale of its ordinary shares through a private placement to new institutional investors, Vivo Capital and Surveyor Capital (a Citadel company).The financing, which is subject to customary closing conditions, is expected to close today, February 25, 2021. Pursuant to the terms of the securities purchase agreement, the Company will issue an aggregate of 25,568,180 ordinary shares (equivalent to 5,113,636 American Depositary Shares (“ADSs”)) at an equivalent price of $3.52 per ADS, equal...